Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell

Status Recruiting

Clinical Trial Summary

It is recommended for patients who underwent an hematopoietic stem cell transplantation to receive 6 months after the graft 3 injections of hexavalent vaccine (diphteria-tetanus- poliomyelitis-pertussis-Hib-HBV) within 2 months followed by a booster dose one month after. The patients included in the study will have a measure of their antibody level against 5 pathogens (diphteria toxin, tetanus toxin, Haemophilus influenza b, hepatitis B virus, poliomyelitis virus) one month after the 3rd injection of hexavalent vaccine. If the antibody response is not sufficient, they will be randomized for a 4th dose in the following month. The antibody response will be again measured one month after the 1 year booster dose.

Clinical Trial Description

It is recommended for patients who underwent an hematopoietic stem cell transplantation to receive, 6 months after the graft, 3 injections of hexavalent vaccine (diphteria-tetanus- poliomyelitis-pertussis-Hib-HBV) within 2 months, followed by a booster dose one yrar after. However, this strategy do not constantly lead to efficient antibody levels.

the investigators aim to determine whether a 4th dose in the initial vaccine schedule (month 0, 1, 2, and 3) allows to obtain a better response.

After informed consent, the investigators will recruit 6 months after the graft 200 patients who had received an hematopoietic stem cell transplantation . The participants will have a measure of their antibody level against 5 pathogens (diphteria toxin, tetanus toxin, Haemophilus influenza b, hepatitis B virus, poliomyelitis virus) at month 0 (before the 1st hexavalent vaccine injection), and one month after the 3rd injection of this vaccine. If the antibody response is not sufficient, they will be randomized for a 4th dose in the following month.

The one year booster dose will be then injected to all participants, and the antibody response will be again measured one month after this dose. The primary endpoint is to compare the antibody levels at this date in patients who had an unsufficient immune response after the 3rd dose and who received or not a 4rth dose in the initial vaccine schedule. ;

Study Design

Related Conditions & MeSH terms

Allograft
Haemopoietic Stem Cell Transplantation

Clinical Trial Details

NCT number	NCT03402776
Study type	Interventional
Source	University Hospital, Grenoble
Contact	Olivier EPAULARD, MD, PhD
Phone	04 76 76 68 13
Email	oepaulard@chu-grenoble.fr
Status	Recruiting
Phase	Phase 3
Start date	May 1, 2018
Completion date	May 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05536492` - Sticky Bone Compared to A-PRF(Platlet Rich Fibrin) Effect on Alveolar Ridge Preservation	N/A
Completed	`NCT00384540` - Cardiac Allograft Vasculopathy and Dobutamine Stress Echocardiography / Brain Natriuretic Peptide Coupling	N/A
Recruiting	`NCT02882828` - PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)	Phase 4
Completed	`NCT02444052` - Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation	N/A
Terminated	`NCT04021316` - Decellularised Dermis Allograft for the Treatment of Chronic Venous Leg Ulceration	N/A
Completed	`NCT00894049` - A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation	Phase 2
Completed	`NCT03829072` - Cooking Education and Adapted Physical Activity in Allografted Patients	N/A
Completed	`NCT03009708` - Feasibility Study of Platelet Activation and Inflammatory Response of Platelets in Hematopoietic Stem Cell Allograft Patients Post-transplant: Spontaneously and After Stimulation by an CMV Antigen	N/A
Terminated	`NCT05258929` - RElapse After Allograft: Link Between LoCus of Control and QualiTy of Life
Recruiting	`NCT05096351` - Immunological Reaction of the Recipient After Cold-stored Saphenous Venous Allograft (Bioprotec)
Not yet recruiting	`NCT05459181` - HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)	N/A
Recruiting	`NCT05164835` - Study of Drug Acceptance and Its Persistence Over Time in Patients Receiving a Haematopoietic Stem Cell Allograft	N/A
Recruiting	`NCT05510011` - Allograft and Tantalum Cone Reconstruction in TKA Revision
Not yet recruiting	`NCT06219473` - Efficacy of Fascia Lata Allograft and Platelet Rich Fibrin on the Periodontal Phenotype Around Dental Implant	Phase 4
Withdrawn	`NCT05423496` - KidneyCare Immuno-optimization in Renal Allografts (KIRA)	N/A
Completed	`NCT00876148` - Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation — EVaxAll

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms